Optinose Inc (OPTN)

$6.38 +0.35 (5.80%)
Market Cap 60.66M
Revenue (ttm) 70.99M
Net Income (ttm) -35.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -49.98%
Debt to Equity Ratio -3.07
Volume 109,700
Avg Vol 71,723
Day's Range N/A - N/A
Shares Out 10.06M
Stochastic %K 59%
Beta -0.15
Analysts Strong Sell
Price Target $30.74

Latest News on OPTN

Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million

Jan 15, 2025, 7:00 AM EST - 2 days ago

Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million

Optinose Announces 1-for-15 Reverse Stock Split

Dec 26, 2024, 7:00 AM EST - 22 days ago

Optinose Announces 1-for-15 Reverse Stock Split

Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference

Dec 2, 2024, 3:53 PM EST - 6 weeks ago

Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference

OptiNose, Inc. (OPTN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 12:47 PM EST - 2 months ago

OptiNose, Inc. (OPTN) Q3 2024 Earnings Call Transcript

Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights

Nov 12, 2024, 7:00 AM EST - 2 months ago

Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights

Optinose Announces Reporting Date for Third Quarter 2024 Financial Results

Nov 5, 2024, 4:30 PM EST - 2 months ago

Optinose Announces Reporting Date for Third Quarter 2024 Financial Results

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 16, 2024, 4:05 PM EDT - 3 months ago

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Optinose Appoints Terry Kohler as Chief Financial Officer

Oct 7, 2024, 4:59 PM EDT - 3 months ago

Optinose Appoints Terry Kohler as Chief Financial Officer

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery

Sep 5, 2024, 9:00 AM EDT - 4 months ago

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery

Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 9:00 AM EDT - 5 months ago

Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference

OptiNose, Inc. (OPTN) Q2 2024 Earnings Call Transcript

Aug 11, 2024, 7:17 AM EDT - 5 months ago

OptiNose, Inc. (OPTN) Q2 2024 Earnings Call Transcript

Optinose Announces Reporting Date for Second Quarter 2024 Financial Results

Aug 2, 2024, 8:30 AM EDT - 6 months ago

Optinose Announces Reporting Date for Second Quarter 2024 Financial Results

Expanded Access to XHANCE with Addition to National Commercial Formularies

Jun 27, 2024, 7:00 AM EDT - 7 months ago

Expanded Access to XHANCE with Addition to National Commercial Formularies

OptiNose, Inc. (OPTN) Q1 2024 Earnings Call Transcript

May 17, 2024, 8:55 PM EDT - 8 months ago

OptiNose, Inc. (OPTN) Q1 2024 Earnings Call Transcript

Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 17, 2024, 12:00 PM EDT - 8 months ago

Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights

May 14, 2024, 7:00 AM EDT - 8 months ago

Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights

Optinose Announces Reporting Date for First Quarter 2024 Financial Results

May 10, 2024, 2:56 PM EDT - 9 months ago

Optinose Announces Reporting Date for First Quarter 2024 Financial Results

Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million

Apr 25, 2024, 7:00 AM EDT - 9 months ago

Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million

Optinose to Present at the Needham Virtual Healthcare Conference

Apr 4, 2024, 4:01 PM EDT - 10 months ago

Optinose to Present at the Needham Virtual Healthcare Conference

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

Mar 15, 2024, 3:34 PM EDT - 11 months ago

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

OptiNose, Inc. (OPTN) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 9:14 AM EST - 11 months ago

OptiNose, Inc. (OPTN) Q4 2023 Earnings Call Transcript

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

Mar 7, 2024, 7:00 AM EST - 11 months ago

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

Feb 29, 2024, 4:40 PM EST - 11 months ago

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

Jan 18, 2024, 12:00 PM EST - 1 year ago

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

Dec 6, 2023, 7:00 AM EST - 1 year ago

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 22, 2023, 9:00 AM EST - 1 year ago

Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

OptiNose, Inc. (OPTN) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 10:04 AM EST - 1 year ago

OptiNose, Inc. (OPTN) Q3 2023 Earnings Call Transcript

Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

Nov 9, 2023, 7:00 AM EST - 1 year ago

Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

Optinose to Present at the 2023 Cantor Global Healthcare Conference

Sep 22, 2023, 9:01 AM EDT - 1 year ago

Optinose to Present at the 2023 Cantor Global Healthcare Conference

Optinose Reports Second Quarter 2023 Financial Results and Operational Updates

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Optinose Reports Second Quarter 2023 Financial Results and Operational Updates

OptiNose: The Worst Has Been Avoided (Rating Upgrade)

Aug 1, 2023, 6:58 PM EDT - 1 year ago

OptiNose: The Worst Has Been Avoided (Rating Upgrade)

Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million

Jul 27, 2023, 7:00 AM EDT - 1 year ago

Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million

Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 16, 2023, 4:08 PM EDT - 1 year ago

Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Optinose to Present at the Jefferies Healthcare Conference

Jun 2, 2023, 1:00 PM EDT - 1 year ago

Optinose to Present at the Jefferies Healthcare Conference

OptiNose Inc. (OPTN) Q1 2023 Earnings Call Transcript

May 11, 2023, 5:57 PM EDT - 1 year ago

OptiNose Inc. (OPTN) Q1 2023 Earnings Call Transcript

Optinose Reports First Quarter 2023 Financial Results and Operational Updates

May 11, 2023, 7:00 AM EDT - 1 year ago

Optinose Reports First Quarter 2023 Financial Results and Operational Updates

Optinose Announces Reporting Date for First Quarter 2023 Financial Results

May 1, 2023, 4:30 PM EDT - 1 year ago

Optinose Announces Reporting Date for First Quarter 2023 Financial Results

OptiNose, Inc. (OPTN) Q4 2022 Earnings Call Transcript

Mar 7, 2023, 2:22 PM EST - 2 years ago

OptiNose, Inc. (OPTN) Q4 2022 Earnings Call Transcript

Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

Mar 7, 2023, 7:00 AM EST - 2 years ago

Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results

Feb 28, 2023, 4:30 PM EST - 2 years ago

Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results

Optinose Announces CEO Transition and Business Update

Jan 31, 2023, 7:00 AM EST - 2 years ago

Optinose Announces CEO Transition and Business Update

Optinose Appoints Paul Spence as Chief Commercial Officer

Dec 15, 2022, 4:30 PM EST - 2 years ago

Optinose Appoints Paul Spence as Chief Commercial Officer

Optinose Announces Departure of Acting Chief Financial Officer

Dec 9, 2022, 8:00 AM EST - 2 years ago

Optinose Announces Departure of Acting Chief Financial Officer

Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference

Nov 30, 2022, 7:00 AM EST - 2 years ago

Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference

Optinose Announces Pricing of Public Offering of Common Stock and Warrants

Nov 21, 2022, 8:30 AM EST - 2 years ago

Optinose Announces Pricing of Public Offering of Common Stock and Warrants

Optinose Announces Proposed Public Offering of Common Stock and Warrants

Nov 21, 2022, 6:12 AM EST - 2 years ago

Optinose Announces Proposed Public Offering of Common Stock and Warrants

OptiNose, Inc. (OPTN) Q3 2022 Earnings Call Transcript

Nov 13, 2022, 7:40 PM EST - 2 years ago

OptiNose, Inc. (OPTN) Q3 2022 Earnings Call Transcript

Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting

Nov 9, 2022, 3:00 PM EST - 2 years ago

Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting

Optinose Announces Reporting Date for Third Quarter 2022 Financial Results

Nov 7, 2022, 3:00 PM EST - 2 years ago

Optinose Announces Reporting Date for Third Quarter 2022 Financial Results

Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022

Oct 21, 2022, 7:00 AM EDT - 2 years ago

Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022